We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Sep 2020 - 09 Sep 2020
Virtual Venue

Different Ways of Measuring HDL Predicts Cardiovascular Disease

By LabMedica International staff writers
Posted on 21 Jul 2020
Print article
Image: Alternative indices of high-density lipoprotein (HDL) quality, such as cholesterol efflux capacity, and HDL quantity, such as HDL particle number predict cardiovascular disease risk (Photo courtesy of Harvard Medical School).
Image: Alternative indices of high-density lipoprotein (HDL) quality, such as cholesterol efflux capacity, and HDL quantity, such as HDL particle number predict cardiovascular disease risk (Photo courtesy of Harvard Medical School).
High-density lipoprotein (HDL) cholesterol is a well-integrated biomarker of cardiometabolic health and remains a key component of the cardiovascular disease (CVD) risk prediction algorithms used to guide therapy.

The static measurement of HDL cholesterol levels, as performed in current clinical practice, may not adequately capture the anti-atherogenic properties of highly heterogeneous HDL particles. Recent studies have suggested that measuring the number of particles of HDL (HDL-P), rather than the total amount of cholesterol that the particles carry (HDL-C) may be a better way of determining the association between HDL and cardiovascular diseases.

Cardiologists at Massachusetts General Hospital (Boston, MA, USA) and their colleagues assessed HDL cholesterol levels, apolipoprotein A-I, cholesterol efflux capacity, and HDL particle number that were evaluated at baseline and 12 months in a nested case-control study. In total, 314 cases of incident cardiovascular disease (CVD) (myocardial infarction, unstable angina, arterial revascularization, stroke, or cardiovascular death) were compared to age- and gender-matched controls.

Fasting lipids, apolipoproteins, hsCRP, and glucose levels were measured in a core laboratory. HDL particle number was measured using nuclear magnetic resonance spectroscopy LipoProfile III by LipoScience, Inc., (Morrisville, NC, USA). Total particle number was calculated to be the sum of levels across HDL subclasses, identified based on lipid methyl group nuclear magnetic resonance signals. Cholesterol efflux capacity was quantified in plasma samples thawed from liquid nitrogen storage using a previously validated cell-based ex vivo assay.

The scientists reported that cholesterol efflux capacity was moderately correlated with HDL cholesterol, apolipoprotein A-I, and HDL particle number. Baseline HDL particle number was inversely associated with incident CVD, whereas no significant association was found for baseline cholesterol efflux capacity, HDL cholesterol or apolipoprotein A-I. The authors found that participants with the highest HDL-P levels had a 34% lower risk of strokes and a 37% lower risk of heart attacks, compared with participants who had the lowest HDL-P levels.

The association was even stronger among women: The highest HDL-P levels were associated with a 46% reduction in strokes and a 49% reduction in heart attacks, compared with the lowest levels. HDL-C levels, the traditional measure of this form of cholesterol, were associated with heart attacks, but not strokes, suggesting that HDL-P may be the better measure of the effects of cholesterol on a person’s heart health. Interestingly, when they looked only at the data from Black participants, they found neither HDL-P nor HDL-C robustly predicted heart attacks.

The authors concluded that in this study, cholesterol efflux capacity was associated with incident CVD in individuals on potent statin therapy but not at baseline. For both baseline and on-statin analyses, HDL particle number was the strongest of four HDL-related biomarkers as an inverse predictor of incident events and biomarker of residual risk. The study was published in the June 2020 issue of the journal Circulation.

Related Links:
Massachusetts General Hospital
LipoScience, Inc



Print article

Channels

Molecular Diagnostics

view channel
Image: The NovaSeq 6000 Sequencing System offers high-throughput sequencing across a broad range of applications (Photo courtesy of Illumina).

Somatic Evolution Identified in Non-Neoplastic IBD-Affected Colon

Inflammatory bowel disease (IBD) is a debilitating disease characterized by repeated flares of intestinal inflammation. The two major subtypes of IBD, Crohn’s disease (CD) and ulcerative colitis (UC) are... Read more

Industry News

view channel
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)

Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years

Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.